Life without COX 2 inhibitors Risks and benefits are determined by dose and potencyEditor-The paper by Kearney et al on the risk of atherothrombosis with cyclooxygenase-
No takes yet. Share an insight, caveat, or question.
Neil J. Sebire (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: